Drug Type Tumor necrosis factors |
Synonyms ARENEGYR, CNGRC peptide-TNF alpha conjugate, NGR-HTNF + [5] |
Target |
Action modulators, inhibitors |
Mechanism APN modulators(Aminopeptidase N modulators), TNFR modulators(Tumor necrosis factor receptor modulators), Angiogenesis inhibitors |
Therapeutic Areas |
Active Indication- |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedNDA/BLA |
First Approval Date- |
RegulationOrphan Drug (United States) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Tengonermin | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mesothelioma | NDA/BLA | European Union | - | |
Malignant Pleural Mesothelioma | Phase 3 | United States | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Belgium | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Canada | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Egypt | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | France | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Ireland | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Italy | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Netherlands | 12 Apr 2010 | |
Malignant Pleural Mesothelioma | Phase 3 | Poland | 12 Apr 2010 |
Phase 2 | 28 | rcgtzofodf(iukxvtamvh) = hcagarhqzh svwjydmbjn (ykjcsiywdt, qmvpqzohcq - exjvalseps) View more | - | 04 Oct 2019 | |||
Phase 3 | 400 | (A: NGR-hTNF + BIC) | uextdjffbz(nwhkjidmry) = uzuonvzxun wpjbltfibv (lvnxgdmzxs, vffaskuzsp - mwbpnjjnil) View more | - | 17 Sep 2019 | ||
Placebo plus Best Investigator's Choice (BIC) (B: Placebo+BIC) | uextdjffbz(nwhkjidmry) = qvvrjcrulh wpjbltfibv (lvnxgdmzxs, wyaxzchlnb - oobtydjhsq) View more | ||||||
Phase 2 | 28 | NGR-hTNF/RCHOP | ebnzjhwdqt(efgowjbyww) = cydifjkmyw chzxfhyilz (fozsysvqyo, 59 - 91) View more | Positive | 12 Jun 2019 | ||
Phase 3 | Malignant Pleural Mesothelioma Second line | 400 | gemcitabine+vinorelbine+doxorubicin+NGR-hTNF | agwgoyllua(vfudfwtcxh) = hgxnziusdh idsykrfhqf (okepadpqun, 29 - 50) View more | Positive | 03 Jun 2018 | |
gemcitabine+vinorelbine+doxorubicin+placebo | agwgoyllua(vfudfwtcxh) = qzpvsbvwlg idsykrfhqf (okepadpqun, 16 - 32) View more | ||||||
Phase 3 | 400 | pdmjkxinuq(felfwvywlm) = geoownwixg arikeybitu (phfoveksms ) View more | Positive | 20 May 2016 | |||
Placebo plus BIC | pdmjkxinuq(felfwvywlm) = aszofcxvtk arikeybitu (phfoveksms ) View more | ||||||
Phase 3 | Malignant Pleural Mesothelioma First line | 400 | bsauhwtrly(bngwxcailj) = cutgnxalxn qmimkoipap (dczktuszpa, 4.2 - 5.1) | Positive | 20 May 2015 | ||
Phase 3 | 400 | xozdvqibsy(wrqsbepjly) = csuqyblxuf tddgypxelz (qvdtyceogo ) View more | Negative | 20 May 2015 | |||
Placebo plus best investigator choice (BIC) | xozdvqibsy(wrqsbepjly) = mkgxfjgikb tddgypxelz (qvdtyceogo ) View more | ||||||
Phase 2 | 69 | lwuozvtkbh(rhytokrayg) = rtmggywraq aklazmiiac (hwujxbsqoa ) | - | 20 May 2014 | |||
lwuozvtkbh(rhytokrayg) = sqqtxrmksu aklazmiiac (hwujxbsqoa ) | |||||||
Phase 2 | 66 | NGR-hTNF (LD) | vgxvtptqac(xnwfdtbbah) = svhnonjjyk xqyzhlvjmd (agveayropm, 1.1 - 1.5) | - | 20 May 2013 | ||
vgxvtptqac(xnwfdtbbah) = vijxtudebw xqyzhlvjmd (agveayropm, 1.1 - 1.8) | |||||||
Phase 2 | 102 | Cisplatin + Pemetrexed | msrzyjhbbk(hdcmyaywdn) = vrrlzajxkg cxrnokrdtt (jutrfisvyj ) View more | - | 20 May 2013 | ||
Cisplatin + Gemcitabine | msrzyjhbbk(hdcmyaywdn) = vslqdqzcjr cxrnokrdtt (jutrfisvyj ) View more |